Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 13/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.31 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.31 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6441740 | 0.91 | CTDSP1 (0.36) | CTDSP1CYP1A2GRIN1GRIN2BP2RX7 | |
| SCHEMBL5827229 | 0.84 | ADRA1D (0.40) | — | |
| SCHEMBL6448402 | 0.83 | CTDSP1 (0.37) | CTDSP1CYP1A2GRIN1GRIN2BBRD4 | |
| SCHEMBL6442051 | 0.78 | PTGDR2 (0.46) | CYP1A2 | |
| SCHEMBL6805497 | 0.78 | CTDSP1 (0.38) | CTDSP1CYP1A2GRIN1GRIN2BP2RX7 | |
| SCHEMBL6444533 | 0.77 | SMN1; SMN2 (0.39) | CTDSP1CYP1A2GRIN1GRIN2B | |
| SCHEMBL6200427 | 0.75 | USP2 (0.42) | — | |
| SCHEMBL6443736 | 0.74 | NPC1 (0.33) | LCK | |
| SCHEMBL6450553 | 0.72 | PDE5A (0.39) | — | |
| SCHEMBL6444199 | 0.69 | SMN1; SMN2 (0.43) | CTDSP1CYP1A2GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6770645-B2 | SEXUAL DISORDERS THERAPY; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS | PFIZER INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030064990-A1 | Pharmaceutically active compounds | PFIZER INC. | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064990-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | CTDSP1 1555/4885CYP1A2 429/4885GRIN1 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.